Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Repositioning of antiarrhythmics for prostate cancer treatment: a novel strategy to reprogram cancer-associated fibroblasts towards a tumor-suppressive phenotype

Fig. 4

Antiarrhythmics affect PCa cell growth by impairing CAF function. a Schematic representation of CM experiment work-flow (Created with Biorender.com). b Graph reporting the growth of DU145 cells cultured with CM from CAFs treated or not with antiarrhythmics, or CM from NPFs at different time points (24, 48, 72 h). c Graph reporting the growth of LNCaP cells cultured with CM from CAFs treated or not with antiarrhythmics, or CM from NPFs at different time points (24, 48, 72 h). d Cell cycle phase distribution of DU145 cells cultured with CM from CAFs treated or not with antiarrhythmics, or CM from NPFs at 72 h until treatment. Results reported in the figure represent the mean (+ SD or ± SD) of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005, Student’s t-test

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us